Identification
NameMycophenolate mofetil
Accession NumberDB00688  (APRD01602)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent, inosine monophosphate dehydrogenase (IMPDH) inhibitor.

Structure
Thumb
Synonyms
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Cellcept
MMF
Mycophenolic acid morpholinoethyl ester
RS 61443
External IDs 168396 / RS 61443 / RS-61443
Product Ingredients
IngredientUNIICASInChI KeyDetails
Mycophenolate mofetil hydrochlorideUXH81S8ZVB 116680-01-4OWLCGJBUTJXNOF-HDNKIUSMSA-NDetails
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-mycophenolate Mofetil CapsulesCapsule250 mgOralAccel Pharma IncNot applicableNot applicableCanada
Accel-mycophenolate Mofetil TabletsTablet500 mgOralAccel Pharma IncNot applicableNot applicableCanada
Ach-mycophenolateCapsule250 mgOralAccord Healthcare Limited2012-05-01Not applicableCanada
CellceptCapsule250 mg/1OralGenentech, Inc.1995-05-03Not applicableUs00004 0259 01 nlmimage10 b8135c6a
CellceptCapsule250 mgOralRoche Registration Limited1996-02-14Not applicableEu
CellceptTablet500 mgOralRoche Registration Limited1996-02-14Not applicableEu
CellceptInjection, powder, lyophilized, for solution500 mg/20mLIntravenousGenentech, Inc.1998-08-12Not applicableUs
CellceptTablet, film coated500 mg/1OralLake Erie Medical Dba Quality Care Produts Llc1997-06-19Not applicableUs00004 0260 01 nlmimage10 5e132f39
CellceptCapsule250 mgOralHoffmann La Roche1995-12-31Not applicableCanada
CellceptTablet, film coated500 mg/1OralGenentech, Inc.1997-06-19Not applicableUs
CellceptPowder, for suspension200 mgOralHoffmann La Roche2002-08-27Not applicableCanada
CellceptInjection, powder, for solution500 mgIntravenousRoche Registration Limited1996-02-14Not applicableEu
CellceptCapsule250 mg/1OralRebel Distributors1995-05-03Not applicableUs
CellceptTablet500 mgOralHoffmann La Roche1998-11-11Not applicableCanada
CellceptCapsule250 mgOralRoche Registration Limited1996-02-14Not applicableEu
CellceptPowder, for suspension200 mg/mLOralGenentech, Inc.1998-10-01Not applicableUs
CellceptCapsule250 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-11-29Not applicableUs
CellceptTablet500 mgOralRoche Registration Limited1996-02-14Not applicableEu
CellceptCapsule250 mg/1OralCardinal Health1995-05-03Not applicableUs
Cellcept I.V.Powder, for solution500 mgIntravenousHoffmann La Roche1999-12-20Not applicableCanada
Co MycophenolateTablet500 mgOralCobalt Laboratories2012-02-14Not applicableCanada
Jamp-mycophenolateTablet500 mgOralJamp Pharma Corporation2012-03-23Not applicableCanada
Jamp-mycophenolate CapsulesCapsule250 mgOralJamp Pharma Corporation2012-06-13Not applicableCanada
Mycophenolate MofetilCapsule250 mgOralSanis Health Inc2016-09-29Not applicableCanada
Mycophenolate MofetilTablet500 mgOralSanis Health Inc2016-09-29Not applicableCanada
Mycophenolate Mofetil for Injection, USPPowder, for solution500 mgIntravenousAccord Healthcare LimitedNot applicableNot applicableCanada
Mycophenolate Mofetil TabletsTablet500 mgOralAccord Healthcare Limited2012-02-16Not applicableCanada
Mylan-mycophenolateTablet500 mgOralMylan Pharmaceuticals2011-11-302017-01-09Canada
Mylan-mycophenolateCapsule250 mgOralMylan Pharmaceuticals2011-11-302017-01-09Canada
Novo-mycophenolateCapsule250 mgOralTeva2011-11-30Not applicableCanada
Novo-mycophenolateTablet500 mgOralTeva2011-11-30Not applicableCanada
Ran-mycophenolateTablet500 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Sandoz Mycophenolate MofetilCapsule250 mgOralSandoz Canada Incorporated2011-11-30Not applicableCanada
Sandoz Mycophenolate MofetilTablet500 mgOralSandoz Canada Incorporated2011-11-30Not applicableCanada
Van-mycophenolateTablet500 mgOralVanc Pharmaceuticals Inc2015-07-22Not applicableCanada
Van-mycophenolateCapsule250 mgOralVanc Pharmaceuticals Inc2015-07-22Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-mycophenolateTablet500 mgOralApotex Corporation2011-12-01Not applicableCanada
Apo-mycophenolateCapsule250 mgOralApotex Corporation2011-12-01Not applicableCanada
Mycophenolate MofetilCapsule250 mg/1OralMylan Pharmaceuticals2009-05-04Not applicableUs
Mycophenolate MofetilInjection, powder, lyophilized, for solution500 mg/20mLIntravenousPar Pharmaceutical2016-10-28Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralApotex Corporation2009-05-04Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralMylan Institutional2009-06-01Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralGreenstone, Llc2010-06-11Not applicableUs
Mycophenolate MofetilTablet500 mg/1OralQualitest2010-07-192015-12-29Us
Mycophenolate MofetilCapsule250 mg/1OralCardinal Health2011-10-25Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralWest Ward Pharmaceutical2008-07-29Not applicableUs00054 0163 29 nlmimage10 d144e897
Mycophenolate MofetilTablet, film coated500 mg/1OralStrides Shasun Limited2010-11-06Not applicableUs
Mycophenolate MofetilTablet500 mg/1OralAccord Healthcare Limited2009-05-04Not applicableUs16729 0019 01 nlmimage10 423c2151
Mycophenolate MofetilTablet, film coated500 mg/1OralMylan Institutional2009-06-01Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralAmerincan Health Packaging2012-07-022017-04-27Us
Mycophenolate MofetilTablet, film coated500 mg/1OralAscend Laboratories, LLC2011-11-28Not applicableUs
Mycophenolate MofetilTablet, coated500 mg/1OralApotex Corporation2009-05-04Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralJubilant Cadista Pharmaceuticals Inc.2013-08-012017-07-18Us
Mycophenolate MofetilCapsule250 mg/1OralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralAmerincan Health Packaging2014-12-15Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralA S Medication Solutions2010-11-062017-06-20Us
Mycophenolate MofetilTablet, film coated500 mg/1OralMylan Pharmaceuticals2009-05-04Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralTeva2009-05-06Not applicableUs00093 7334 01 nlmimage10 a929548a
Mycophenolate MofetilCapsule250 mg/1OralCadila Pharnmaceuticals2009-05-04Not applicableUs
Mycophenolate MofetilTablet500 mg/1OralA S Medication Solutions2009-05-042017-06-20Us
Mycophenolate MofetilCapsule250 mg/1OralGolden State Medical Supply2015-01-06Not applicableUs
Mycophenolate MofetilTablet, coated500 mg/1OralAmerincan Health Packaging2012-07-022015-12-31Us
Mycophenolate MofetilTablet500 mg/1OralWest Ward Pharmaceutical2008-07-29Not applicableUs00054 0166 25 nlmimage10 6a1db56d
Mycophenolate MofetilCapsule250 mg/1OralStrides Shasun Limited2010-11-06Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralAccord Healthcare Limited2009-05-04Not applicableUs16729 0094 01 nlmimage10 c13be0af
Mycophenolate MofetilCapsule250 mg/1OralZydus Pharmaceuticals Usa, Inc.2009-05-04Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralAscend Laboratories, LLC2010-01-01Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralGreenstone, Llc2010-06-11Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralQualitest2010-03-162015-12-29Us
Mycophenolate MofetilTablet, film coated500 mg/1OralCardinal Health2011-10-25Not applicableUs
Mycophenolate MofetilTablet500 mg/1OralAmerincan Health Packaging2014-12-15Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralSandoz2008-10-15Not applicableUs
Mycophenolate MofetilTablet500 mg/1OralSandoz2008-10-15Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralTeva2009-05-05Not applicableUs00093 7477 01 nlmimage10 9b294dca
Mycophenolate MofetilTablet, film coated500 mg/1OralCadila Pharnmaceuticals2009-05-04Not applicableUs
Mycophenolate MofetilInjection, powder, lyophilized, for solution500 mg/20mLIntravenousAkorn2017-02-28Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralGolden State Medical Supply2015-01-06Not applicableUs
Mycophenolate MofetilPowder, for suspension200 mg/mLOralAscend Laboratories, LLC2014-11-17Not applicableUs
Mycophenolate MofetilTablet, film coated500 mg/1OralAv Pak2016-08-25Not applicableUs
Mycophenolate MofetilCapsule250 mg/1OralJubilant Cadista Pharmaceuticals Inc.2013-08-012017-07-18Us
Mycophenolate MofetilTablet, film coated500 mg/1OralZydus Pharmaceuticals Usa, Inc.2009-05-04Not applicableUs68382 0131 01 nlmimage10 9d08cee6
Mycophenolate Mofetil TevaCapsule250 mgOralTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaTablet, film coated500 mgOralTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaCapsule250 mgOralTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaTablet, film coated500 mgOralTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaTablet, film coated500 mgOralTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaCapsule250 mgOralTeva Pharma B.V.2008-02-21Not applicableEu
MyfenaxTablet, film coated500 mgOralTeva B.V.2008-02-21Not applicableEu
MyfenaxCapsule250 mgOralTeva B.V.2008-02-21Not applicableEu
MyfenaxCapsule250 mgOralTeva B.V.2008-02-21Not applicableEu
MyfenaxTablet, film coated500 mgOralTeva B.V.2008-02-21Not applicableEu
MyfenaxCapsule250 mgOralTeva B.V.2008-02-21Not applicableEu
MyfenaxTablet, film coated500 mgOralTeva B.V.2008-02-21Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CellCept Oral Suspension Genentech USA, Inc.
CellCept IntravenousGenentech USA, Inc.
Brand mixturesNot Available
Categories
UNII9242ECW6R0
CAS number128794-94-5
WeightAverage: 433.4947
Monoisotopic: 433.210052351
Chemical FormulaC23H31NO7
InChI KeyRTGDFNSFWBGLEC-SYZQJQIISA-N
InChI
InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+
IUPAC Name
2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate
SMILES
COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C
Pharmacology
Indication

For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids.

Structured Indications
Pharmacodynamics

Mycophenolate mofetil is a prodrug of mycophenolic acid (MPA), an antibiotic substance derived from Penicillium stoloniferum. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.

Mechanism of action

Mycophenolate mofetil is hydrolyzed to form mycophenolic acid (MPA), which is the active metabolite. MPA is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways, MPA has potent cytostatic effects on lymphocytes. MPA inhibits proliferative responses of T- and B-lymphocytes to both mitogenic and allospecific stimulation. Addition of guanosine or deoxyguanosine reverses the cytostatic effects of MPA on lymphocytes. MPA also suppresses antibody formation by B-lymphocytes. MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection. Mycophenolate mofetil did not inhibit early events in the activation of human peripheral blood mononuclear cells, such as the production of interleukin-1 (IL-1) and interleukin-2 (IL-2), but did block the coupling of these events to DNA synthesis and proliferation.

TargetKindPharmacological actionActionsOrganismUniProt ID
Inosine-5'-monophosphate dehydrogenase 1Proteinyes
inhibitor
HumanP20839 details
Inosine-5'-monophosphate dehydrogenase 2Proteinyes
inhibitor
HumanP12268 details
Related Articles
Absorption

Rapidly absorbed following oral administration. In 12 healthy volunteers, the mean absolute bioavailability of oral mycophenolate mofetil relative to intravenous mycophenolate mofetil (based on MPA AUC) was 94%. The absolute bioavailability of the delayed release tablet in stable renal transplant patients on cyclosporin is 72%. Food (27 g fat, 650 calories) has no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil.

Volume of distribution
  • 3.6 ±1.5 L/kg [intravenous, healthy subjects, MPA]
  • 4 ±1.2 L/kg [oral administration, healthy subjects, MPA]
Protein binding

MPA (the active metabolite), at clinically relevant concentrations, is over 98% bound to plasma albumin. The phenolic glucuronide of MPA, mycophenolic acid glucuronide (MPAG) has 82% protein bound.

Metabolism

Following oral and intravenous dosing, mycophenolate mofetil undergoes complete metabolism to MPA, the active metabolite. Metabolism to MPA occurs presystemically after oral dosing. MPA is metabolized principally by glucuronyl transferase to form the phenolic glucuronide of MPA (MPAG) which is not pharmacologically active. In vivo, MPAG is converted to MPA via enterohepatic recirculation. The following metabolites of the 2-hydroxyethyl-morpholino moiety are also recovered in the urine following oral administration of mycophenolate mofetil to healthy subjects: N-(2-carboxymethyl)-morpholine, N-(2-hydroxyethyl)-morpholine, and the N-oxide of N-(2-hydroxyethyl)-morpholine. Cytochrome P450 isozymes, CYP3A4/5 and to a lesser extent by CYP2C8, is responsible for the biotransformation of MPA to 6-O-desmethyl-mycophenolic acid.

SubstrateEnzymesProduct
Mycophenolate mofetil
Not Available
Mycophenolic acid (MPA)Details
Mycophenolate mofetil
Not Available
Mycophenolic acid glucuronideDetails
Mycophenolate mofetil
Not Available
N-(2-carboxymethyl)-morpholineDetails
Mycophenolate mofetil
Not Available
N-(2-hydroxyethyl)-morpholineDetails
Mycophenolate mofetil
Not Available
N-(2-hydroxyethyl)-morpholine N-oxideDetails
Route of elimination

Negligible amount of drug is excreted as MPA (< 1% of dose) in the urine. When orally administered, mycophenolate mofetil was completely recovered with 93% of the dose found in the urine and 6% found in feces. 87% of the administered dose is excreted in the urine as MPAG.

Half life

The mean elimination half-life for mycophenolic acid (the active metabolite) ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.

Clearance
  • 193 mL/min [plasma clearance, MPA, oral administration]
  • 177 mL/min [plasma clearance, MPA, IV administration]
  • 15.5 mL/min [renal clearance, MPAG, delayed-release tablet]
Toxicity

Oral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Mycophenolic Acid Metabolism PathwayDrug metabolismSMP00652
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 5-androstenedione.Experimental, Illicit
AbciximabMycophenolate mofetil may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Abiraterone.Approved
AcebutololMycophenolate mofetil may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Aceclofenac.Approved
AcenocoumarolMycophenolate mofetil may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinMycophenolate mofetil may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mycophenolate mofetil.Approved
AfatinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Alclometasone.Approved
AldosteroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Alectinib.Approved
Alendronic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Alendronic acid.Approved
AlfentanilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Alfentanil.Approved, Illicit
AliskirenMycophenolate mofetil may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololMycophenolate mofetil may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
AmantadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amantadine.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Amcinonide.Approved
AmikacinMycophenolate mofetil may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMycophenolate mofetil may decrease the antihypertensive activities of Amiloride.Approved
Aminohippuric acidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Mycophenolate mofetil can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Amprenavir.Approved
AmrubicinMycophenolate mofetil may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AmsacrineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amsacrine.Approved
AncrodMycophenolate mofetil may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with HMPL-004.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 4-Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Antipyrine.Approved
Antithrombin III humanMycophenolate mofetil may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanMycophenolate mofetil may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Acetovanillone.Investigational
ApramycinMycophenolate mofetil may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinMycophenolate mofetil may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinMycophenolate mofetil may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanMycophenolate mofetil may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMycophenolate mofetil may decrease the antihypertensive activities of Arotinolol.Approved
AstemizoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Mycophenolate mofetil can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Atorvastatin.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Azapropazone.Withdrawn
AzelastineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolate mofetil.Approved
AzithromycinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Azithromycin.Approved
BalsalazideMycophenolate mofetil may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Mycophenolate mofetil.Investigational
BecaplerminMycophenolate mofetil may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMycophenolate mofetil may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mycophenolate mofetil.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mycophenolate mofetil.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Benoxaprofen.Withdrawn
BenzocaineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mycophenolate mofetil.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Betamethasone.Approved, Vet Approved
BetaxololMycophenolate mofetil may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Betulinic Acid.Investigational
BevantololMycophenolate mofetil may decrease the antihypertensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
BiperidenThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Biperiden.Approved
BisoprololMycophenolate mofetil may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMycophenolate mofetil may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Mycophenolate mofetil can be decreased when combined with Boceprevir.Withdrawn
BopindololMycophenolate mofetil may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Mycophenolate mofetil can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bosutinib.Approved
BromfenacThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bucillamine.Investigational
BucindololMycophenolate mofetil may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Budesonide.Approved
BufuralolMycophenolate mofetil may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideMycophenolate mofetil may decrease the diuretic activities of Bumetanide.Approved
BupranololMycophenolate mofetil may decrease the antihypertensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Candesartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mycophenolate mofetil.Experimental
CaptoprilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Mycophenolate mofetil can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mycophenolate mofetil.Approved
CarprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololMycophenolate mofetil may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Caspofungin.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Celecoxib.Approved, Investigational
CeliprololMycophenolate mofetil may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ceritinib.Approved
CertoparinMycophenolate mofetil may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Vet Approved
ChlorpromazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mycophenolate mofetil.Approved
CholesterolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Cholic Acid.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Trisalicylate-choline.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ciclesonide.Approved, Investigational
CilazaprilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Cimetidine.Approved
CinoxacinMycophenolate mofetil may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Citalopram.Approved
Citric AcidMycophenolate mofetil may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Mycophenolate mofetil can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Mycophenolate mofetil can be decreased when combined with Clemastine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clodronate.Approved, Investigational, Vet Approved
ClofazimineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clonixin.Approved
ClopidogrelThe metabolism of Mycophenolate mofetil can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Mycophenolate mofetil can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Mycophenolate mofetil can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Curcumin.Investigational
CyclophosphamideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineMycophenolate mofetil may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Mycophenolate mofetil can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateMycophenolate mofetil may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dactinomycin.Approved
DalteparinMycophenolate mofetil may increase the anticoagulant activities of Dalteparin.Approved
DarexabanMycophenolate mofetil may increase the anticoagulant activities of Ym150.Investigational
DarunavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinMycophenolate mofetil may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Mycophenolate mofetil can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Mycophenolate mofetil.Approved
DesipramineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Desipramine.Approved
DesirudinMycophenolate mofetil may increase the anticoagulant activities of Desirudin.Approved
DesloratadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desoximetasone.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mycophenolate mofetil.Approved
DextranMycophenolate mofetil may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Mycophenolate mofetil may increase the anticoagulant activities of Dextran 40.Approved
DextromethorphanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mycophenolate mofetil.Approved, Vet Approved
DiclofenacThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolMycophenolate mofetil may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mycophenolate mofetil.Approved
DihydroergotamineThe metabolism of Mycophenolate mofetil can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Mycophenolate mofetil can be decreased when combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Mycophenolate mofetil.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mycophenolate mofetil.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mycophenolate mofetil.Approved
DipyridamoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dipyridamole.Approved
DoxazosinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Doxepin.Approved
DoxorubicinMycophenolate mofetil may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Mycophenolate mofetil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Mycophenolate mofetil can be decreased when combined with Dronedarone.Approved
DrospirenoneMycophenolate mofetil may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ebselen.Investigational
Edetic AcidMycophenolate mofetil may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMycophenolate mofetil may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Elbasvir.Approved
EltrombopagThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mycophenolate mofetil.Approved
EnoxacinMycophenolate mofetil may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinMycophenolate mofetil may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Epirizole.Approved
EpirubicinMycophenolate mofetil may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMycophenolate mofetil may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolate mofetil.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolate mofetil.Approved
EquileninThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Equilin.Approved
ErgonovineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Mycophenolate mofetil can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololMycophenolate mofetil may decrease the antihypertensive activities of Esmolol.Approved
EstramustineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Estrone sulfate.Approved
Etacrynic acidMycophenolate mofetil may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolate mofetil.Approved, Investigational
Ethyl biscoumacetateMycophenolate mofetil may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etofenamate.Approved
EtoposideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mycophenolate mofetil.Approved
FentanylThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fidaxomicin.Approved
FingolimodMycophenolate mofetil may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinMycophenolate mofetil may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mycophenolate mofetil.Approved, Withdrawn
FluconazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fludrocortisone.Approved
FluindioneMycophenolate mofetil may increase the anticoagulant activities of Fluindione.Investigational
FlumequineMycophenolate mofetil may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluorometholone.Approved
FluoxetineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluprednidene.Approved, Withdrawn
FlurandrenolideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flurandrenolide.Approved
FlurazepamThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Mycophenolate mofetil can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mycophenolate mofetil.Approved, Nutraceutical, Vet Approved
FondaparinuxMycophenolate mofetil may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMycophenolate mofetil may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mycophenolate mofetil.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mycophenolate mofetil.Approved
FosphenytoinThe metabolism of Mycophenolate mofetil can be increased when combined with Fosphenytoin.Approved
FramycetinMycophenolate mofetil may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMycophenolate mofetil may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with G17DT.Investigational
GabexateMycophenolate mofetil may increase the anticoagulant activities of Gabexate.Investigational
GatifloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Gefitinib.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Withdrawn
GemfibrozilThe metabolism of Mycophenolate mofetil can be decreased when combined with Gemfibrozil.Approved
GemifloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinMycophenolate mofetil may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Genistein.Investigational
GentamicinMycophenolate mofetil may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMycophenolate mofetil may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GlyburideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Glyburide.Approved
Gramicidin DThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with HE3286.Investigational
HeparinMycophenolate mofetil may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Higenamine.Investigational
HydralazineMycophenolate mofetil may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Vet Approved
HydrocortisoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mycophenolate mofetil.Approved
IbandronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Icatibant.Approved
IdarubicinMycophenolate mofetil may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Idelalisib.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
ImatinibThe metabolism of Mycophenolate mofetil can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Mycophenolate mofetil.Investigational
ImipramineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Imipramine.Approved
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolate mofetil.Approved
IndenololMycophenolate mofetil may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Indoprofen.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with INGN 225.Investigational
IrbesartanThe metabolism of Mycophenolate mofetil can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Mycophenolate mofetil can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Mycophenolate mofetil can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ivermectin.Approved, Vet Approved
KanamycinMycophenolate mofetil may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Kebuzone.Experimental
KetamineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mycophenolate mofetil.Approved
LabetalolMycophenolate mofetil may decrease the antihypertensive activities of Labetalol.Approved
LandiololMycophenolate mofetil may decrease the antihypertensive activities of Aop200704.Investigational
LansoprazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Leflunomide.Approved, Investigational
LepirudinMycophenolate mofetil may increase the anticoagulant activities of Lepirudin.Approved
LevobunololMycophenolate mofetil may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Mycophenolate mofetil.Approved
LiothyronineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Mycophenolate mofetil.Approved
LomefloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Lomefloxacin.Approved
LomitapideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Loratadine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lornoxicam.Approved
LosartanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Mycophenolate mofetil can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
LuliconazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Magnesium salicylate.Approved
MaprotilineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mycophenolate mofetil.Approved
ME-609The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with ME-609.Investigational
MebendazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mefenamic acid.Approved
MefloquineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meloxicam.Approved, Vet Approved
MeprobamateThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMycophenolate mofetil may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Metamizole.Withdrawn
MethadoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mycophenolate mofetil.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolate mofetil.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Methylprednisolone.Approved, Vet Approved
MetipranololMycophenolate mofetil may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolate mofetil.Approved
MetoprololThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Metoprolol.Approved, Investigational
MetrizamideMycophenolate mofetil may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MibefradilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mycophenolate mofetil.Approved
MitomycinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mizoribine.Investigational
ModafinilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mycophenolate mofetil.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mycophenolate mofetil.Approved
MorphineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nabumetone.Approved
NadololMycophenolate mofetil may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMycophenolate mofetil may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMycophenolate mofetil may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NafcillinThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Naftifine.Approved
Nalidixic AcidMycophenolate mofetil may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaltrexoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Naproxen.Approved, Vet Approved
NaringeninThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with NCX 1022.Investigational
NeamineMycophenolate mofetil may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe metabolism of Mycophenolate mofetil can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Nelfinavir.Approved
NeomycinMycophenolate mofetil may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NeostigmineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nepafenac.Approved
NetilmicinMycophenolate mofetil may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Mycophenolate mofetil can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Mycophenolate mofetil can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nimesulide.Approved, Withdrawn
NisoldipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nitroaspirin.Investigational
NorethisteroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Norethisterone.Approved
NorfloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe metabolism of Mycophenolate mofetil can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mycophenolate mofetil.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Olopatadine.Approved
OlsalazineMycophenolate mofetil may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Mycophenolate mofetil.Investigational
OmeprazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Osimertinib.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxaprozin.Approved
OxprenololMycophenolate mofetil may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxyphenbutazone.Withdrawn
P-NitrophenolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Palmitic Acid.Experimental
PamidronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pamidronate.Approved
PantoprazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Parecoxib.Approved
ParomomycinMycophenolate mofetil may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Paroxetine.Approved, Investigational
PazufloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololMycophenolate mofetil may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Mycophenolate mofetil can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateMycophenolate mofetil may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Perindopril.Approved
PhenindioneMycophenolate mofetil may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Mycophenolate mofetil can be increased when combined with Phenobarbital.Approved
PhenprocoumonMycophenolate mofetil may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Mycophenolate mofetil can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolate mofetil.Approved, Investigational
PimozideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pimozide.Approved
PindololMycophenolate mofetil may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Mycophenolate mofetil can be decreased when combined with Pioglitazone.Approved, Investigational
PirarubicinMycophenolate mofetil may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMycophenolate mofetil may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolate mofetil.Approved, Investigational
Platelet Activating FactorThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Platelet Activating Factor.Experimental
PlicamycinMycophenolate mofetil may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mycophenolate mofetil.Approved
PonatinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololMycophenolate mofetil may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mycophenolate mofetil.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with dehydroepiandrosterone sulfate.Investigational
PravastatinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Mycophenolate mofetil can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Propacetamol.Approved
PropafenoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Mycophenolate mofetil.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Mycophenolate mofetil.Experimental
Protein S humanMycophenolate mofetil may increase the anticoagulant activities of Protein S human.Approved
ProtriptylineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Protriptyline.Approved
PrulifloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with PTC299.Investigational
PuromycinMycophenolate mofetil may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuercetinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mycophenolate mofetil.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mycophenolate mofetil.Approved
QuinidineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mycophenolate mofetil.Approved
RanitidineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Regorafenib.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mycophenolate mofetil.Approved
ReserpineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Resveratrol.Experimental, Investigational
ReviparinMycophenolate mofetil may increase the anticoagulant activities of Reviparin.Approved
RibostamycinMycophenolate mofetil may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe metabolism of Mycophenolate mofetil can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Mycophenolate mofetil can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Mycophenolate mofetil can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Rimexolone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with CDX-110.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Risedronate.Approved, Investigational
RitonavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanMycophenolate mofetil may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Rofecoxib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Mycophenolate mofetil.Approved
RolapitantThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Rolapitant.Approved
RosiglitazoneThe metabolism of Mycophenolate mofetil can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinMycophenolate mofetil may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Mycophenolate mofetil.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mycophenolate mofetil.Experimental
SaquinavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Mycophenolate mofetil can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Seratrodast.Approved
SertralineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Mycophenolate mofetil can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mycophenolate mofetil.Approved
SirolimusThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Sirolimus.Approved, Investigational
SisomicinMycophenolate mofetil may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolMycophenolate mofetil may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMycophenolate mofetil may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinMycophenolate mofetil may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Mycophenolate mofetil.Approved
SpironolactoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with SRT501.Investigational
St. John's WortThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StaurosporineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Stiripentol.Approved
StreptomycinMycophenolate mofetil may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMycophenolate mofetil may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfamethoxazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineMycophenolate mofetil may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfinpyrazoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Mycophenolate mofetil.Approved
SulodexideMycophenolate mofetil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Mycophenolate mofetil.Investigational
SumatriptanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Suprofen.Approved, Withdrawn
TacrineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Mycophenolate mofetil.Approved, Investigational
TacrolimusThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tacrolimus.Approved, Investigational
TacrolimusMycophenolate mofetil may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Mycophenolate mofetil.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mycophenolate mofetil.Approved
TamoxifenThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tamoxifen.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mycophenolate mofetil.Approved
Taurocholic AcidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Technetium Tc-99m Medronate.Approved
TelaprevirThe metabolism of Mycophenolate mofetil can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Mycophenolate mofetil can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Mycophenolate mofetil.Experimental, Investigational
TemsirolimusThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Temsirolimus.Approved
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mycophenolate mofetil.Approved
TerazosinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Testosterone.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Mycophenolate mofetil can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tiludronate.Approved, Vet Approved
TimololMycophenolate mofetil may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tixocortol.Approved
TobramycinMycophenolate mofetil may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tocilizumab.Approved
TofacitinibMycophenolate mofetil may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mycophenolate mofetil.Approved
TolvaptanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Tolvaptan.Approved
TorasemideMycophenolate mofetil may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mycophenolate mofetil.Approved
TranilastThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Mycophenolate mofetil.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolate mofetil.Approved
TrazodoneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolate mofetil.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMycophenolate mofetil may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Vet Approved
TrifluoperazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Trimipramine.Approved
TrovafloxacinMycophenolate mofetil may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mycophenolate mofetil.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinMycophenolate mofetil may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolate mofetil.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Mycophenolate mofetil.Approved
VenlafaxineThe metabolism of Mycophenolate mofetil can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Mycophenolate mofetil can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinMycophenolate mofetil may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMycophenolate mofetil may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Mycophenolate mofetil can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zomepirac.Withdrawn
ZorubicinMycophenolate mofetil may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Do not take calcium, aluminium, magnesium or iron supplements within 2 hours of taking this medication.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
References
Synthesis Reference

Roger C. Fu, De-Mei Leung, Jeffrey S. Fleitman, Michele C. Rizzolio, Andrew R. Miksztal, "Process for preparing pharmaceutical compositions containing crystalline anhydrous mycophenolate mofetil salts." U.S. Patent US5545637, issued November, 1988.

US5545637
General References
  1. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS: Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess. 2005 May;9(21):1-179, iii-iv. [PubMed:15899149 ]
  2. Picard N, Cresteil T, Premaud A, Marquet P: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8. [PubMed:15570183 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (200 KB)
MSDSDownload (82.3 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentAcute Kidney Injury (AKI)1
0CompletedTreatmentDisseminated Sclerosis1
0CompletedTreatmentImmunosuppression / Transplantation, Renal1
0WithdrawnTreatmentMultiple Myeloma (MM) / Myeloma-Multiple1
1Active Not RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / CD45-Positive Neoplastic Cells Present / Chronic Myelomonocytic Leukemia / Previously Treated Myelodysplastic Syndromes / Refractory Anemia With Excess Blasts / Refractory Anemia With Ring Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts1
1Active Not RecruitingTreatmentAdenosine Deaminase Deficiency / Autosomal Recessive Disorder / Immune System Disorder / Purine-Nucleoside Phosphorylase Deficiency / Severe Combined Immunodeficiency / Severe Combined Immunodeficiency With Absence of T and B Cells / X-linked Severe Combined Immunodeficiency1
1Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentChronic Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts / Secondary Acute Myeloid Leukemia1
1CompletedNot AvailableDrug Interactions / Healthy Volunteers / Pharmacokinetics of ASP015K1
1CompletedNot AvailableHealthy Volunteers5
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Plasma Mycophenolic Acid (MPA) / Pharmacokinetics of Plasma Phenolic Glucuronide of MPA (MPAG)1
1CompletedNot AvailableTransplant, Kidney1
1CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Leukemia, Prolymphocytic / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
1CompletedTreatmentAcute Myeloid Leukaemias (AML) / Leukemia Lymphoblastic, Acute / Neoplasm Recurrent1
1CompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / Congenital Hypoplastic Anemia / Previously Treated Myelodysplastic Syndromes1
1CompletedTreatmentBlood And Marrow Transplantation / Leukemias / Malignant Lymphomas / Transplantation Infection / Transplantation, Bone Marrow1
1CompletedTreatmentCongenital Urological Abnormalities1
1CompletedTreatmentDiffuse Cutaneous Systemic Sclerosis1
1CompletedTreatmentDrug Interaction Potentiation1
1CompletedTreatmentFasting1
1CompletedTreatmentFed1
1CompletedTreatmentGranulomatosis With Polyangiitis / Vasculitis1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1CompletedTreatmentLeukemias / Myelodysplastic Syndrome1
1CompletedTreatmentMicroscopic Polyangiitis / MPO-ANCA Vasculitis1
1CompletedTreatmentMalignancies, Hematologic1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1RecruitingTreatmentAcute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Adult Acute Lymphoblastic Leukemia in Complete Remission / Childhood Acute Lymphoblastic Leukemia in Complete Remission / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia1
1RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Secondary Acute Myeloid Leukemia1
1RecruitingTreatmentAgnogenic Myeloid Metaplasia / Leukemias / Malignant Lymphomas / Smith-Magenis Syndrome1
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
1RecruitingTreatmentPreviously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Hematologic Malignancy1
1RecruitingTreatmentSickle Cell Disorders1
1RecruitingTreatmentTransplantation, Liver1
1SuspendedTreatmentPlasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1TerminatedTreatmentAcute Myeloid Leukaemias (AML) / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome1
1TerminatedTreatmentAplastic Anaemia (AA)1
1TerminatedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Secondary Myelofibrosis1
1TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1TerminatedTreatmentTransplant, Kidney1
1Unknown StatusTreatmentPost Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil1
1WithdrawnTreatmentCutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides and Sezary Syndrome / Stage IIB Mycosis Fungoides and Sezary Syndrome / Stage IIIA Mycosis Fungoides and Sezary Syndrome / Stage IIIB Mycosis Fungoides and Sezary Syndrome / Stage IVA Mycosis Fungoides and Sezary Syndrome / Stage IVB Mycosis Fungoides and Sezary Syndrome1
1WithdrawnTreatmentLeukemias / Malignant Lymphomas / Pediatric Disorders / Transplantation, Stem Cell1
1, 2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Childhood Renal Cell Carcinoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Clear Cell Renal Cell Carcinoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Renal Cell Cancer / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Anemia / Refractory Anemia With Ringed Sideroblasts / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Renal Cell Cancer / T-Cell Large Granular Lymphocyte Leukemia / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Aggressive Non-Hodgkin Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Previously Treated Myelodysplastic Syndromes / Recurrent Chronic Lymphocytic Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Indolent Adult Non-Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Plasma Cell Myeloma / Refractory Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Malignant mast cell neoplasm / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Myeloid/NK-cell Acute Leukemia / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Systemic Amyloidosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Renal Cell Cancer / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Multiple Myeloma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia in Remission / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndrome / Childhood Renal Cell Carcinoma / Chronic Myelomonocytic Leukemia / Clear Cell Renal Cell Carcinoma / De Novo Myelodysplastic Syndrome / Metastatic Renal Cell Cancer / Previously Treated Myelodysplastic Syndromes / Progression of Multiple Myeloma or Plasma Cell Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Refractory Anemia / Refractory Anemia With Ringed Sideroblasts / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Renal Medullary Carcinoma / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
1, 2Active Not RecruitingTreatmentComplete Atypical DiGeorge Anomaly / Complete Atypical DiGeorge Syndrome / Complete DiGeorge Anomaly / Complete DiGeorge Syndrome / DiGeorge Anomaly1
1, 2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
1, 2Active Not RecruitingTreatmentLeukemia, Prolymphocytic / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Refractory Small Lymphocytic Lymphoma / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia1
1, 2Active Not RecruitingTreatmentRecurrent Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2CompletedTreatmentCNI Side Effects1
1, 2CompletedTreatmentCancer, Breast / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Renal Cancers1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias / Malignant Lymphomas1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions1
1, 2CompletedTreatmentKidney Diseases / Renal Failure / Transplantation, Kidney1
1, 2CompletedTreatmentKidney Diseases / Transplant, Kidney / Transplantation, Kidney / Transplantation, Renal1
1, 2CompletedTreatmentLeukemias2
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1, 2CompletedTreatmentMalignancies, Hematologic1
1, 2CompletedTreatmentSickle Cell Disorders1
1, 2Not Yet RecruitingTreatmentAge-Related Macular Degeneration (ARMD)1
1, 2RecruitingPreventionAdult Hodgkin Lymphoma / Adult Myelodysplastic Syndrome / Agnogenic Myeloid Metaplasia / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Hodgkin Lymphoma / Childhood Myelodysplastic Syndrome / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Non-Hodgkin's lymphoma1
1, 2RecruitingPreventionHypertension, Renal / Stress, Psychological1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / CD45-Positive Neoplastic Cells Present / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome With Excess Blasts / Recurrent Adult Acute Myeloid Leukemia / Refractory Adult Acute Lymphoblastic Leukemia1
1, 2RecruitingTreatmentAdult Living Donor Kidney Transplant Recipients / Living Kidney Donors / Transplant, Kidney1
1, 2RecruitingTreatmentBeta Thalassemia-Major / Sickle Cell Disorders1
1, 2RecruitingTreatmentCongenital Hypoplastic Anemia1
1, 2RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
1, 2RecruitingTreatmentLeukemias / Malignant Lymphomas1
1, 2RecruitingTreatmentLeukemias / Myeloproliferative Diseases1
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2TerminatedTreatmentGraft Versus Host Disease (GVHD) / Lupus Erythematosus1
1, 2Unknown StatusTreatmentEnd Stage Renal Disease (ESRD) / Transplant, Kidney1
1, 2Unknown StatusTreatmentEnd-Stage Renal Disease (ESRD) / Renal Failure1
1, 2Unknown StatusTreatmentLeukaemia, Acute / Myelodysplastic Syndrome / Tumors, Solid1
1, 2Unknown StatusTreatmentTransplantation, Renal / Uremia1
1, 2WithdrawnTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Nonmalignant Neoplasm1
2Active Not RecruitingPreventionChronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Leukaemia, Acute / Lymphoma, B-Cell / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Myelodysplasia / Small Lymphocytic Lymphoma (SLL)1
2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3- / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Lymphoma / Childhood Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Burkitt Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Plasma Cell Myeloma / Secondary Myelodysplastic Syndromes / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Immunoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Burkitt Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Contiguous Immunoblastic Lymphoma / Stage II Adult Non-Contiguous Immunoblastic Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Burkitt Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Burkitt Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma / Stage II Contiguous Adult Diffuse Small Cleaved Cell Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage II Non-Contiguous Adult Burkitt Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage II Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Burkitt Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Burkitt Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Aplastic Anaemia (AA) / Burkitt's Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Congenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Paroxysmal Nocturnal Haemoglobinuria (PNH) / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Severe Combined Immunodeficiency / Severe Congenital Neutropenia / Shwachman-Diamond Syndrome / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM) / Wiskott-Aldrich Syndrome (WAS)1
2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Leukemia, Prolymphocytic / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Small Lymphocytic Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Multiple Myeloma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Small Lymphocytic Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome / Testicular Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAccelerated Phase of Disease / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase of Disease / Recurrent Disease1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Graft Versus Host Disease (GVHD) / Lymphoma, Hodgkins / Myelodysplastic/Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Lymphocytic Leukaemia (CLL) / Immune System Diseases / Malignant Lymphomas / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Leukemias / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Malignant mast cell neoplasm / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAcute myeloid leukaemia (in remission) / Congenital Hypoplastic Anemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentAdrenoleukodystrophy (ALD) / Alpha Mannosidosis / Aspartylglucosaminuria / Fucosidosis / Hunter Syndrome / Hurler's Syndrome / Krabbe's Disease / Metachromatic Leukodystrophy (MLD) / Mucopolysaccharidosis / Mucopolysaccharidosis VI / Peroxisomal Disorders / Sly Syndrome / Sphingolipidoses1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Relapsing Chronic Myelogenous Leukemia1
2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Previously Treated Myelodysplastic Syndromes / Progressive Hairy Cell Leukemia, Initial Treatment / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Splenic Marginal Zone Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentAnemias / Bone Marrow Transplant Failure / Myelodysplastic Syndromes (MDS) / Myeloid Leukemias / Myeloproliferative Disorders / Neural Tube Defects (NTDs)1
2Active Not RecruitingTreatmentAtypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Essential Thrombocythemia (ET) / Myeloproliferative Neoplasms / Paroxysmal Nocturnal Haemoglobinuria (PNH) / Polycythemia Vera (PV) / Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase / Primary Myelofibrosis / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ring Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts1
2Active Not RecruitingTreatmentB-Cell Chronic Lymphocytic Leukemia / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentB-Cell Prolymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Leukemia, Prolymphocytic / Recurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / T-Cell Prolymphocytic Leukemia1
2Active Not RecruitingTreatmentBlood Stem Cell Transplant Failure / Leukemias / Malignancies, Hematologic1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Prolymphocytic / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma / T-Cell Large Granular Lymphocyte Leukemia1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2Active Not RecruitingTreatmentHematopoietic/Lymphoid Cancer1
2Active Not RecruitingTreatmentHemoglobinuria, Paroxysmal Nocturnal (PNH) / Juvenile Myelomonocytic Leukemia (JMML) / Leukemia, Acute Lymphocytic (ALL) / Leukemia, Myeloid, Acute(AML) / Leukemia, Myeloid, Chronic(CML) / Lymphoma, Hodgkins / Lymphoma, Non-Hodgkin (NHL) / Myelodysplastic Syndromes (MDS)1
2Active Not RecruitingTreatmentImmunodeficiency Syndrome / Non-Cancer Diagnosis1
2Active Not RecruitingTreatmentJuvenile Myelomonocytic Leukemia1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Plasma Cell Neoplasms / Renal Cancers1
2Active Not RecruitingTreatmentLeukemias / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentRefractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentSickle Cell Disorders1
2Active Not RecruitingTreatmentTransplantation, Kidney2
2CompletedNot AvailableDiabetes, Diabetes Mellitus Type 11
2CompletedPreventionBlood and Marrow Transplant (BMT) / Leukemias / Non-Hodgkin's Lymphoma (NHL)1
2CompletedPreventionDe Novo Kidney Transplantation1
2CompletedPreventionDiabetes, Diabetes Mellitus Type 11
2CompletedPreventionImmunosuppression / Kidney Failure,Chronic / Transplantation, Kidney1
2CompletedPreventionLiver Dysfunction / Rejection, Transplant / Transplantation, Liver1
2CompletedPreventionRejection, Transplant / Transplantation, Kidney / Transplantation, Renal1
2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hematopoietic/Lymphoid Cancer / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL) / Peripheral T-Cell Lymphoma (PTCL)1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Aplastic Anaemia (AA) / Biphenotypic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Hodgkins Disease (HD) / Malignant Lymphomas / Myelodysplastic Syndromes / Plasma Cell Neoplasms1
2CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Leukemia, Prolymphocytic / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Splenic Marginal Zone Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAdrenoleukodystrophy / Gangliosidosis, GM1 / I-Cell Disease / Leukodystrophy, Globoid Cell / Metachromatic Leukodystrophy / Sandhoffs Disease / Sanfilippo Syndrome / Tay Sachs Disease / Wolman's Disease1
2CompletedTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Childhood Acute Lymphoblastic Leukemia in Remission / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentAlcoholic Hepatitis (AH)1
2CompletedTreatmentAllogeneic Blood and Marrow Transplantation (BMT) / Graft Versus Host Disease (GVHD)1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentAplastic Anaemia (AA)1
2CompletedTreatmentBeta-Thalassemia / Hematologic Diseases / Hematopoietic Stem Cell Transplantation (HSCT) / Sickle Cell Disorders1
2CompletedTreatmentBlood Cancers / CLL / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Leukemias / Malignancies / NHL / Smith-Magenis Syndrome1
2CompletedTreatmentBlood Cancers / Leukemias1
2CompletedTreatmentBlood Cancers / Multiple Myeloma (MM)1
2CompletedTreatmentCervical Cancers / Vaginal Cancers1
2CompletedTreatmentChronic Diseases / Leukaemia, Acute / Leukemias / Malignant Lymphomas / Myelodysplasia1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentDiabetic Nephropathies / Hypertension, Renal / IgA Glomerulonephritis / Kidney Failure,Chronic2
2CompletedTreatmentDisorder Related to Renal Transplantation1
2CompletedTreatmentDisseminated Sclerosis1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Immune System Disorders1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Secondary Myelofibrosis1
2CompletedTreatmentGranulomatosis With Polyangiitis / Microscopic Polyangiitis / Renal Limited Vasculitis1
2CompletedTreatmentGranulomatosis With Polyangiitis / Vasculitis1
2CompletedTreatmentHaematological Malignancies1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentInterstitial Lung Disease (ILD) / Scleroderma1
2CompletedTreatmentJuvenile Neuronal Ceroid Lipofuscinosis1
2CompletedTreatmentLeukemias1
2CompletedTreatmentLeukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentLeukemias / Malignant Lymphomas2
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Myeloproliferative Neoplasms / Plasma Cell Neoplasms1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes3
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes2
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentLiver Diseases / Transplantation, Liver1
2CompletedTreatmentMalignancies, Hematologic1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentMyelodysplastic Syndromes1
2CompletedTreatmentNeoplasms, Malignant1
2CompletedTreatmentNephritis, Lupus2
2CompletedTreatmentRenal Cancers1
2CompletedTreatmentTo Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients1
2CompletedTreatmentTransplantation, Kidney3
2CompletedTreatmentTransplantation, Liver1
2Enrolling by InvitationTreatmentGraft Versus Host Disease (GVHD)1
2Enrolling by InvitationTreatmentSjogren's Syndrome1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Aggressive Non-Hodgkin Lymphoma / Hematopoietic Cell Transplantation Recipient / Leukemia, Prolymphocytic / Loss of Chromosome 17p / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasms / Recurrent Chronic Lymphocytic Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Hodgkin Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Recurrent Waldenstrom Macroglobulinemia / T-cell chronic lymphocytic leukaemia1
2Not Yet RecruitingTreatmentHematopoietic/Lymphoid Cancer1
2Not Yet RecruitingTreatmentInterstitial Lung Disease (ILD) / Scleroderma, Systemic1
2Not Yet RecruitingTreatmentSevere Aplastic Anemia (SAA)1
2RecruitingPreventionAcute Leukemia in Remission / Chronic Myeloid Leukemia (CML) / Chronic Myelomonocytic Leukemia / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL) / Primary Myelofibrosis1
2RecruitingPreventionAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Lymphocytic Leukaemia (CLL) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingPreventionAcute myeloid leukaemia (in remission) / Adult Acute Lymphoblastic Leukemia in Complete Remission / Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission / Chronic Myelomonocytic Leukemia in Remission / Graft Versus Host Disease (GVHD) / Lymphoma, Hodgkins / Minimal Residual Disease / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma / Severe Aplastic Anemia (SAA) / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingPreventionAdult Acute Lymphoblastic Leukemia / Adult Acute Myeloid Leukemia / Adult Diffuse Large B-Cell Lymphoma / Aggressive Non-Hodgkin Lymphoma / Childhood Acute Lymphoblastic Leukemia / Childhood Acute Myeloid Leukemia / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Diffuse Large B -Cell Lymphoma / DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Leukemia, Prolymphocytic / Myelodysplastic/Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Aggressive Adult Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Lymphocytic Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Stage I Adult Hodgkin Lymphoma / Stage I Aggressive Adult Non-Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Diffuse Large B-Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Contiguous Adult Aggressive Non-Hodgkin Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Non-Contiguous Aggressive Adult Non-Hodgkin Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage II Small Lymphocytic Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Aggressive Adult Non-Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Diffuse Large B-Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Aggressive Adult Non-Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Small Lymphocytic Lymphoma / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingPreventionChronic Myeloid Leukemia (CML) / Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Myelodysplastic Syndromes1
2RecruitingPreventionGraft Versus Host Disease (GVHD) / Haematological Malignancies1
2RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Biphenotypic Leukemia (ABL) / Acute Leukemias of Ambiguous Lineage / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Graft Versus Host Disease (GVHD) / Lymphoma, Lymphoblastic / Myelodysplastic Syndrome With Excess Blasts / Myelodysplastic Syndrome With Excess Blasts-1 / Myelodysplastic Syndrome With Excess Blasts-2 / RAEB-1 / RAEB-2 / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Anemia With Excess Blasts1
2RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Cytopenia With Multilineage Dysplasia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Erythroid Leukemia in Remission / Acute Leukemia in Remission / Acute Megakaryoblastic Leukemia / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Acute Myeloid Leukemia With FLT3/ITD Mutation / Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 / Acute Myeloid Leukemia With Inv(3)(q21q26.2); RPN1-EVI1 / Acute Myeloid Leukemia With Multilineage Dysplasia / Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214 / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Complete Remission / B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) / B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Burkitt's Lymphoma / Childhood Acute Lymphoblastic Leukemia in Complete Remission / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Myelodysplastic Syndrome / Recurrent Anaplastic Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma / Secondary Acute Myeloid Leukemia / T Lymphoblastic Lymphoma1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma / Acute Myelogenous Leukaemia (AML) / Acute Undifferentiated Leukemia (AUL) / Chemotherapy-sensitive Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Myelodysplastic Syndromes (MDS)1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute erythroid leukemia / Acute Lymphoblastic Leukemia in Remission / Acute Megakaryoblastic Leukemia / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Blasts Under 10 Percent of Bone Marrow Nucleated Cells / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts / Pancytopenia / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Secondary Acute Myeloid Leukemia1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Complete Remission / Adult Acute Myeloid Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Aggressive Non-Hodgkin Lymphoma / Agnogenic Myeloid Metaplasia / B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) / Burkitt's Lymphoma / Childhood Acute Lymphoblastic Leukemia in Complete Remission / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Leukemia, Prolymphocytic / Lymphoma, Lymphoblastic / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome With Excess Blasts / Pancytopenia / Plasma Cell Myeloma / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Lymphocytic Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia With Excess Blasts1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Myelodysplastic Syndrome / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Myelodysplastic Syndrome / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / RAEB-2 / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Anemia With Excess Blasts / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive1
2RecruitingTreatmentAcute Lymphoblastic Leukemia/Lymphoma / Acute Myeloid Leukaemias (AML) / Biphenotypic/Undifferentiated/Prolymphocytic Leukemias / Bone Marrow Failure Syndromes / Burkitt's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Leukaemia, Acute / Leukemia or MDS in Aplasia / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Lymphoma, Hodgkins / Lymphoma, Large-Cell / Lymphoma, Mantle-Cell / Lymphoplasmacytic Lymphoma / Marginal Zone B-Cell Lymphoma / MRD Positive Leukemia / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms/Myelofibrosis / Myeloproliferative Syndromes / Natural Killer Cell Malignancies / Recurrent Cutaneous T-cell lymphoma / Relapsed Chronic Lymphocytic Leukemia / Relapsed Multiple Myeloma / Relapsed Small Lymphocytic Lymphoma / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Burkitt's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Hematological Diseases / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Lymphoma, B-Cell / Lymphoma, Lymphoblastic / Lymphoma, Mantle-Cell / Lymphoplasmacytic Lymphoma / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Myeloproliferative Syndromes / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Leukemia, Prolymphocytic / Leukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL) / Refractory Anemia / Smith-Magenis Syndrome1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Syndromes / Non-Hodgkin's Lymphoma (NHL) / Other Diseases of Blood and Blood-Forming Organs1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML)2
2RecruitingTreatmentAcute myeloid leukaemia (in remission) / Acute Myeloid Leukaemias (AML) / Aplastic Anaemia (AA) / Chronic Myelomonocytic Leukemia / Indolent Non-Hodgkin's Lymphomas / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Neoplasms, Malignant / Plasma Cell Myeloma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ring Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Aplastic Anaemia (AA) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Essential Thrombocythemia (ET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Anemia / Refractory Anemia With Ringed Sideroblasts / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Urticaria Pigmentosa / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Acute Myeloid Leukemia / Adult Diffuse Large B-Cell Lymphoma / Adult Myelodysplastic Syndrome / Adult Non-Hodgkin's Lymphoma / Aggressive Non-Hodgkin Lymphoma / Childhood Acute Lymphoblastic Leukemia / Childhood Acute Myeloid Leukemia / Childhood Diffuse Large B -Cell Lymphoma / Childhood Myelodysplastic Syndrome / Childhood Non-Hodgkin's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia in Remission / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Hematopoietic and Lymphoid Cell Neoplasm / Leukemia, Prolymphocytic / Mantle Cell Lymphoma (MCL) / Plasma Cell Myeloma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentAgnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Chronic Myelomonocytic Leukemia / Chronic Myeloproliferative Disorders / Essential Thrombocythemia (ET) / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myelodysplastic Syndromes / Plasma Cell Dyscrasia / Plasma Cell Neoplasms / Polycythemia Vera (PV) / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Neuroepithelial Tumor / Tumors, Solid1
2RecruitingTreatmentAplastic Anaemia (AA) / Bone Marrow Failure / Immunosuppression / Severe Aplastic Anemia (SAA)1
2RecruitingTreatmentAplastic Anaemia (AA) / Dyskeratosis Congenita / Hoyeraal Hreidarsson Syndrome / Revesz Syndrome1
2RecruitingTreatmentAplastic Anaemia (AA) / Immunodeficiency Syndrome / Non-Cancer Diagnosis / Severe Aplastic Anemia (SAA)1
2RecruitingTreatmentAutoimmune Diseases1
2RecruitingTreatmentB-Cell Prolymphocytic Leukemia / Hypodiploidy / Leukemia, Plasma Cell / Loss of Chromosome 17p / Progression of Multiple Myeloma or Plasma Cell Leukemia / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Non-Hodgkin's lymphoma / Refractory Plasma Cell Myeloma / Refractory Small Lymphocytic Lymphoma / T(14;16) / T(4;14) / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentBone Marrow Failure Syndromes / Severe Aplastic Anemia (SAA)1
2RecruitingTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndrome / De Novo Myelodysplastic Syndrome / Leukemias / Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Childhood Acute Myeloid Leukemia / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
2RecruitingTreatmentChronic Graft Versus Host Disease1
2RecruitingTreatmentEpidermolysis Bullosa2
2RecruitingTreatmentFibrolamellar Hepatocellular Carcinoma / Hepatocellular Carcinoma (Fibrolamellar Variant) / Hepatocellular,Carcinoma1
2RecruitingTreatmentFocal Segmental Glomerulosclerosis (FSGS) / Transplantation, Kidney1
2RecruitingTreatmentGraft Survival / HLA-mismatched Bone Marrow Transplantation / Myeloablative Conditioning / Transplantion, Bone Marrow1
2RecruitingTreatmentHaematological Malignancies2
2RecruitingTreatmentHematopoietic and Lymphoid Cell Neoplasm1
2RecruitingTreatmentHenoch-Schoenlein Purpura Nephritis1
2RecruitingTreatmentInterstitial Lung Disease (ILD) / Scleroderma / Sclerosis, Progressive Systemic1
2RecruitingTreatmentLPL Deficiency1
2RecruitingTreatmentLeukemia, Lymphocytic / Leukemias / Lymphoma, Hodgkins / Malignant Lymphomas / Plasma Cell Myeloma1
2RecruitingTreatmentLeukemias1
2RecruitingTreatmentLeukemias / Malignant Lymphomas1
2RecruitingTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myeloproliferative Disorders1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentNon-Malignant1
2RecruitingTreatmentPost-Transplant Lymphoproliferative Disorder / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Burkitt Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
2RecruitingTreatmentPrimary Myelofibrosis / Secondary Myelofibrosis1
2RecruitingTreatmentRefractory Non-Hodgkin's lymphoma / Relapsed Non Hodgkin Lymphoma1
2RecruitingTreatmentScleroderma, Systemic1
2RecruitingTreatmentSickle Cell Disorders2
2RecruitingTreatmentSystemic Lupus Erythematosus (SLE)1
2RecruitingTreatmentTransplant, Kidney1
2SuspendedTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Aggressive Non-Hodgkin Lymphoma / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Indolent Non-Hodgkin's Lymphomas / Malignant Lymphoma, Large Cell Type / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Chronic Lymphocytic Leukemia / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Follicular Lymphoma / Refractory Hodgkin Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma / Refractory Small Lymphocytic Lymphoma / T-Cell Non-Hodgkin Lymphoma1
2SuspendedTreatmentAcute Myeloid Leukaemias (AML) / B-cell Non-Hodgkin's Lymphomas / Chronic Lymphocytic Leukaemia (CLL) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / T-Cell Non-Hodgkin Lymphoma1
2SuspendedTreatmentCrohn's Disease (CD)1
2TerminatedPreventionCardiac Allograft Vasculopathy / Heart Transplant Recipients1
2TerminatedPreventionGraft Versus Host Disease (GVHD)1
2TerminatedPreventionImmunosuppression in Solid Organ Transplant1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / All / AML / Chronic Lymphocytic Leukaemia (CLL) / CLL / Leukemias / Lymphoma, Hodgkins / Malignancies, Hematologic / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelocytic Leukemia / Chronic Myelocytic Leukemia / Granulocytic Sarcoma / Hodgkin's or Non-Hodgkin's Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome1
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Hodgkins Disease (HD) / Leukemia, Lymphoblastic, Acute / Leukemia, Myeloid, Acute / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood1
2TerminatedTreatmentHaematological Malignancies / Leukemias / Malignant Lymphomas / Myelodysplastic Syndrome1
2TerminatedTreatmentHematologic Diseases1
2TerminatedTreatmentKidney Transplant Recipients1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myeloproliferative Disorders1
2TerminatedTreatmentLeukemias / Myelodysplastic Syndromes1
2TerminatedTreatmentMalignant Lymphomas1
2TerminatedTreatmentNephritis, Lupus2
2TerminatedTreatmentPediatric Liver Transplantation1
2TerminatedTreatmentPrimary Renal Allograft Candidate / Transplantation, Kidney1
2TerminatedTreatmentPrimary Simultaneous Kidney and Pancreas Allograft Candidates / Simultaneous Kidney and Pancreas Transplantation1
2TerminatedTreatmentRenal Cancers1
2TerminatedTreatmentSickle Cell Disorders1
2TerminatedTreatmentTransplantation, Kidney / Transplantation, Renal1
2Unknown StatusTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2Unknown StatusTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
2Unknown StatusTreatmentBlood and Marrow Transplant (BMT) / Multiple Myeloma (MM) / Transplantation, Autologous / Transplantation, Homologous1
2Unknown StatusTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Precancerous Conditions1
2Unknown StatusTreatmentHematopoietic/Lymphoid Cancer1
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
2Unknown StatusTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2Unknown StatusTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2Unknown StatusTreatmentRenal Cancers1
2WithdrawnTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2WithdrawnTreatmentAge-Related Macular Degeneration (ARMD)1
2WithdrawnTreatmentAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis1
2WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 11
2WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2WithdrawnTreatmentNeuroblastomas1
2WithdrawnTreatmentRenal Cancers1
2WithdrawnTreatmentScleroderma, Systemic1
2WithdrawnTreatmentSystemic Lupus Erythematosus (SLE)1
2, 3CompletedTreatmentDisseminated Sclerosis1
2, 3CompletedTreatmentEnd Stage Renal Disease (ESRD)1
2, 3CompletedTreatmentFamilial Lipoprotein Lipase Deficiency1
2, 3CompletedTreatmentVasculitis1
2, 3RecruitingTreatmentChronic Myeloid Leukemia (CML)1
2, 3RecruitingTreatmentCongenital Hypoplastic Anemia1
2, 3RecruitingTreatmentDelayed Graft Function1
2, 3TerminatedTreatmentNephritis, Lupus1
2, 3TerminatedTreatmentSystemic Lupus Erythematosus (SLE)1
2, 3Unknown StatusTreatmentFamilial Lipoprotein Lipase Deficiency1
2, 3WithdrawnTreatmentTransplantation, Kidney1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Aggressive Non-Hodgkin Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Hematopoietic and Lymphoid Cell Neoplasm / Indolent Non-Hodgkin's Lymphomas / Leukemia, Prolymphocytic / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Chronic Lymphocytic Leukemia / Recurrent Plasma Cell Myeloma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Hodgkin Lymphoma / Small Lymphocytic Lymphoma (SLL) / T-cell chronic lymphocytic leukaemia / Waldenstrom's Macroglobulinemia (WM)1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Aggressive Non-Hodgkin Lymphoma / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Hematopoietic and Lymphoid Cell Neoplasm / Indolent Non-Hodgkin's Lymphomas / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic/Myeloproliferative Neoplasms / Plasma Cell Myeloma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
3Active Not RecruitingTreatmentChronic Inflammatory Demyelinating Polyradiculopathy1
3Active Not RecruitingTreatmentIgA Nephropathy1
3Active Not RecruitingTreatmentNephritis, Lupus1
3Active Not RecruitingTreatmentPrevention of Acute Rejection in Paediatric Recipients of a Renal Transplant1
3Active Not RecruitingTreatmentTransplantation, Kidney1
3CompletedPreventionPediatric Kidney Transplantation1
3CompletedPreventionTransplantation, Kidney3
3CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Myelodysplastic Syndrome / Natural Killer Cell Lymphoblastic Leukemia/Lymphoma1
3CompletedTreatmentAcute Myeloid Leukaemias (AML)1
3CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Acute Myeloid Leukemia/Transient Myeloproliferative Disorder / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
3CompletedTreatmentEnd Stage Liver Diseases / Impaired Renal Function1
3CompletedTreatmentGlomerulonephritis, Membranous / Glomerulosclerosis, Focal Segmental1
3CompletedTreatmentGlomerulonephritis, Membranous / Nephritis, Lupus1
3CompletedTreatmentGlomerulosclerosis, Focal Segmental1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Immune System Disorders1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Transplantation, Kidney1
3CompletedTreatmentHeart Diseases / Heart Transplantation1
3CompletedTreatmentHeart Transplantation1
3CompletedTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentHost vs Graft Reaction / Transplantation Immunology / Transplantation, Kidney1
3CompletedTreatmentHost vs Graft Reaction / Transplantation Immunology / Transplantation, Liver1
3CompletedTreatmentIdiopathic Nephrotic Syndrome1
3CompletedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentMyasthenia Gravis1
3CompletedTreatmentMyasthenia Gravis Generalised1
3CompletedTreatmentMyasthenia Gravis, Generalized1
3CompletedTreatmentNephritis, Lupus4
3CompletedTreatmentNephritis, Lupus / Systemic Lupus Erythematosus (SLE)1
3CompletedTreatmentPemphigus Vulgaris (PV)1
3CompletedTreatmentRejection, Transplant1
3CompletedTreatmentTransplant, Kidney1
3CompletedTreatmentTransplantation, Kidney6
3CompletedTreatmentTransplantation, Liver2
3CompletedTreatmentTransplantation, Lung2
3CompletedTreatmentTransplantation, Renal1
3CompletedTreatmentUveitis1
3Enrolling by InvitationNot AvailableDiabetes, Diabetes Mellitus Type 1 / Islet Transplantation1
3Not Yet RecruitingPreventionTransplantation, Liver1
3Not Yet RecruitingTreatmentImmune Thrombocytopenia2
3RecruitingSupportive CareAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Acute Myeloid Leukaemias (AML) / Leukemia, Myeloid, Acute / Myelogenous Leukemia, Acute1
3RecruitingTreatmentFailing Renal Allograft / Transplant, Kidney1
3RecruitingTreatmentGlomerulonephritis, Membranous1
3RecruitingTreatmentGraft Versus Host Disease (GVHD)2
3RecruitingTreatmentInterstitial Lung Disease (ILD) / Scleroderma / Sclerosis, Progressive Systemic1
3RecruitingTreatmentLung Diseases, Interstitial1
3RecruitingTreatmentPemphigus Vulgaris (PV)1
3RecruitingTreatmentTakayasu's Disease1
3RecruitingTreatmentUveitis1
3SuspendedTreatmentSystemic Lupus Erythematosus, Lupus Nephritis1
3TerminatedPreventionCardiovascular Disease (CVD) / Transplantation, Kidney1
3TerminatedPreventionEvidence of Liver Transplantation1
3TerminatedTreatmentANCA Associated Systemic Vasculitis Including Wegener’s / Granulomatosis and Microscopic Polyangiitis and / Renal Limited Vasculitis1
3TerminatedTreatmentAcute Myeloid Leukaemias (AML) / Leukemias / Myeloid Leukemias1
3TerminatedTreatmentAnti-r-HuEpo Associated PRCA Subjects1
3TerminatedTreatmentAtherosclerosis / Renal Failure1
3TerminatedTreatmentCancers1
3TerminatedTreatmentFrequent Relapsing Nephrotic Syndrome / Steroid Dependent Nephrotic Syndrome1
3TerminatedTreatmentIgA Nephropathy1
3TerminatedTreatmentInterstitial Cystitis / Painful Bladder Syndrome (PBS)1
3TerminatedTreatmentNephritis, Lupus2
3Unknown StatusTreatmentGranulomatosis With Polyangiitis / Vasculitis1
3Unknown StatusTreatmentIgA Nephropathy1
3Unknown StatusTreatmentNonneoplastic Condition1
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD) / End Stage Renal Disease (ESRD) / Hemodialysis-dependent patients / Renal Replacement Therapies / Transplantation, Renal1
4Active Not RecruitingTreatmentGlomerulonephritis, Membranous / Nephrotic Syndrome Secondary to Idiopathic Membranous Glomerulonephritis1
4Active Not RecruitingTreatmentTransplantation, Renal1
4CompletedNot AvailableAcute Rejection of Renal Transplant1
4CompletedNot AvailableEnd Stage Renal Disease (ESRD)1
4CompletedPreventionAdverse Effects / Transplantation, Kidney1
4CompletedPreventionChronic Hepatitis C Infection1
4CompletedPreventionDisorder Related to Renal Transplantation1
4CompletedPreventionMaintenance Kidney Transplant1
4CompletedPreventionRenal Transplanted Recipients1
4CompletedPreventionTransplantation, Kidney3
4CompletedSupportive CareTransplantation, Renal1
4CompletedTreatmentAdult Primary Kidney Transplantation1
4CompletedTreatmentAtherosclerosis / Systemic Lupus Erythematosus (SLE)1
4CompletedTreatmentBK Virus Infection1
4CompletedTreatmentBioavailability / Concomitant Medication After Renal Transplantation / Drug Interactions / Immunosuppressive Medication After Renal Transplantation1
4CompletedTreatmentChronic Hepatitis C Infection / End Stage Liver Diseases / Transplantation, Liver1
4CompletedTreatmentChronic Kidney Disease (CKD) / Transplantation, Kidney1
4CompletedTreatmentDe Novo Kidney Transplantation1
4CompletedTreatmentDe Novo Renal Transplant Recipient1
4CompletedTreatmentEnd-Stage Renal Disease (ESRD)1
4CompletedTreatmentGlomerulonephritis minimal lesion1
4CompletedTreatmentHeart Transplant Recipients / Kidney Transplant Recipients1
4CompletedTreatmentHeart Transplantation2
4CompletedTreatmentIgA Nephropathy1
4CompletedTreatmentInflammatory Reaction1
4CompletedTreatmentKidney Diseases1
4CompletedTreatmentKidney Failure,Chronic / Renal Insufficiency,Chronic / Transplantation, Kidney1
4CompletedTreatmentLiver Diseases1
4CompletedTreatmentNephritis, Lupus2
4CompletedTreatmentPrimary Renal Allograft1
4CompletedTreatmentRejection, Transplant / Renal Failure / Transplantation, Kidney1
4CompletedTreatmentRenal Function and Chronic Allograft Vasculopathy1
4CompletedTreatmentTransplant, Kidney3
4CompletedTreatmentTransplantation, Kidney10
4CompletedTreatmentTransplantation, Liver5
4CompletedTreatmentTransplantation, Renal2
4CompletedTreatmentUveitis1
4Enrolling by InvitationTreatmentEfficacy and Safety / Mycophenolate Mofetil / Neuromyelitis Optica Spectrum Disorders1
4Not Yet RecruitingTreatmentGastrointestinal Disorder, Functional / Kidney Transplant Rejection1
4RecruitingPreventionAcute Graft Versus Host Disease1
4RecruitingPreventionBeta-Thalassemia Major1
4RecruitingTreatmentDrug Interaction Potentiation / Transplantation, Kidney1
4RecruitingTreatmentFunction of Renal Transplant1
4RecruitingTreatmentHepatitis, Autoimmune1
4RecruitingTreatmentHepatocellular,Carcinoma1
4RecruitingTreatmentIgA Nephropathy1
4RecruitingTreatmentImmunosuppression1
4RecruitingTreatmentNephritis, Lupus2
4RecruitingTreatmentThalassemia Major (TM)1
4TerminatedPreventionHeart Transplantation / Renal Function Abnormal1
4TerminatedTreatmentDelayed Graft Function / Transplantation, Kidney1
4TerminatedTreatmentHeart Transplantation1
4TerminatedTreatmentImpaired Renal Function / Liver Transplant Candidates / Renal Failure1
4TerminatedTreatmentKidney Transplant Failure and Rejection1
4TerminatedTreatmentLung and Heart-lung Transplantation1
4TerminatedTreatmentStable Renal Transplant Recipients1
4TerminatedTreatmentTransplantation, Kidney3
4TerminatedTreatmentTransplantation, Renal1
4TerminatedTreatmentTransplants and Implants1
4Unknown StatusPreventionDiabetes / Rejection, Transplant1
4Unknown StatusPreventionKidney; Complications, Allograft1
4Unknown StatusPreventionRenal Failure / Transplantation, Kidney1
4Unknown StatusTreatmentCardiac Transplant1
4Unknown StatusTreatmentEvidence of Liver Transplantation1
4Unknown StatusTreatmentHepatitis1
4Unknown StatusTreatmentKidney Transplant Recipients1
4Unknown StatusTreatmentTransplant, Kidney1
4Unknown StatusTreatmentTransplantation, Organ1
4WithdrawnNot AvailablePlasmapheresis / Transplantation, Kidney1
4WithdrawnTreatmentCardiovascular Disease (CVD) / Cardiovascular Outcomes / Kidney Transplant Recipients / Transplantation, Kidney1
Not AvailableActive Not RecruitingPreventionTransplantation, Liver1
Not AvailableActive Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / B-Cell Chronic Lymphocytic Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Childhood Renal Cell Carcinoma / Chronic Phase Chronic Myelogenous Leukemia / Clear Cell Renal Cell Carcinoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Splenic Marginal Zone Lymphoma / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer / T-Cell Large Granular Lymphocyte Leukemia / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentAcute Myeloid Leukemia/Transient Myeloproliferative Disorder / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Malignant mast cell neoplasm / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Systemic Amyloidosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Multiple Myeloma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Multiple Myeloma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentEnd Stage Renal Failure With Renal Transplant1
Not AvailableActive Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
Not AvailableAvailableNot AvailableComplete DiGeorge Anomaly / Complete DiGeorge Syndrome / DiGeorge Anomaly / DiGeorge's syndrome1
Not AvailableCompletedNot AvailableEarly Diffuse Cutaneous Systemic Sclerosis1
Not AvailableCompletedNot AvailableGI Disturbance1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableImmune Thrombocytopenia1
Not AvailableCompletedNot AvailablePediatric Heart Transplant Recipients / Pediatric Heart Transplantation1
Not AvailableCompletedNot AvailableTransplantation, Kidney1
Not AvailableCompletedPreventionAbsence; Kidney1
Not AvailableCompletedScreeningRenal Failure, Chronic1
Not AvailableCompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Aggressive NK-cell Leukemia / AIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Primary CNS Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Essential Thrombocythemia (ET) / Extramedullary Plasmacytoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / HIV-associated Hodgkin Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Intraocular Lymphoma / Isolated Plasmacytoma of Bone / Juvenile Myelomonocytic Leukemia / Leukemia, Prolymphocytic / Malignant mast cell neoplasm / Meningeal Chronic Myelogenous Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Myeloid/NK-cell Acute Leukemia / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Central Nervous System Lymphoma (PCNSL) / Primary Myelofibrosis / Primary Systemic Amyloidosis / Progressive Hairy Cell Leukemia, Initial Treatment / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Small Lymphocytic Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Multiple Myeloma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Small Lymphocytic Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableCompletedTreatmentAnti-Neutrophil Cytoplasmic Antibody / Vasculitis1
Not AvailableCompletedTreatmentArthritis / Systemic Lupus Erythematosus (SLE)1
Not AvailableCompletedTreatmentChronic Kidney Disease (CKD) / Transplantation, Liver1
Not AvailableCompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
Not AvailableCompletedTreatmentEnd-Stage Renal Disease (ESRD)1
Not AvailableCompletedTreatmentGraft Versus Host Disease (GVHD)1
Not AvailableCompletedTreatmentGraft Versus Host Disease (GVHD) / Mucositis1
Not AvailableCompletedTreatmentGranulomatous Disease, Chronic / Metabolism, Inborn Errors1
Not AvailableCompletedTreatmentHeart Transplantation2
Not AvailableCompletedTreatmentHenoch-Schoenlein Purpura (HSP) / Nephritis1
Not AvailableCompletedTreatmentIgA Nephropathy1
Not AvailableCompletedTreatmentIgA Nephropathy (IgAN)1
Not AvailableCompletedTreatmentImmunosuppression1
Not AvailableCompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
Not AvailableCompletedTreatmentLysosomal Storage Diseases / Peroxisomal Disorders1
Not AvailableCompletedTreatmentNephritis, Lupus2
Not AvailableCompletedTreatmentProphylaxis of Organ Rejection4
Not AvailableCompletedTreatmentScleroderma, Systemic1
Not AvailableCompletedTreatmentTransplant, Kidney1
Not AvailableNo Longer AvailableNot AvailableDiabetes, Diabetes Mellitus Type 11
Not AvailableNo Longer AvailableNot AvailableLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous Conditions / Secondary Myelofibrosis1
Not AvailableNot Yet RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Agnogenic Myeloid Metaplasia / Burkitt's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Lymphoblastic / Lymphoma, Mantle-Cell / Lymphoplasmacytic Lymphoma / Marginal Zone B-Cell Lymphoma / Multiple Myeloma (MM) / Myelodysplasia / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL)1
Not AvailableRecruitingNot AvailableIgA Nephropathy / Immunosuppressive Treatment / Proteinuria in Nephrotic Range1
Not AvailableRecruitingNot AvailableKidney; Complications, Allograft / Transplantation Infection1
Not AvailableRecruitingNot AvailableNephritis, Lupus1
Not AvailableRecruitingNot AvailableTransplantation, Kidney1
Not AvailableRecruitingBasic ScienceNephritis, Lupus1
Not AvailableRecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Agnogenic Myeloid Metaplasia / Chronic Myelogenous Leukemia (CML) / Lymphoid Malignancies / Lymphoma, Hodgkins / Myelodysplastic Syndromes / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Relapsed Chronic Lymphocytic Leukemia / Relapsed Non-Hodgkin's Lymphoma1
Not AvailableRecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
Not AvailableRecruitingTreatmentAllografts / Transplantation, Lung1
Not AvailableRecruitingTreatmentChronic Myeloid Leukemia (CML) / Leukaemia, Acute / Myelodysplastic Syndrome1
Not AvailableRecruitingTreatmentChronic Myelomonocytic Leukemia-2 / High Grade Malignant Neoplasm / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts-2 / Myeloid Neoplasm / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia1
Not AvailableRecruitingTreatmentDiabetes1
Not AvailableRecruitingTreatmentDisorder Related to Renal Transplantation / Effects of Immunosuppressant Therapy1
Not AvailableRecruitingTreatmentGraft Versus Host Disease (GVHD) / Hematopoietic/Lymphoid Cancer1
Not AvailableRecruitingTreatmentHaemoglobinopathies congenital / Sickle Cell Disorders1
Not AvailableRecruitingTreatmentIgA Nephropathy1
Not AvailableRecruitingTreatmentImmunosuppression1
Not AvailableRecruitingTreatmentMalignancies, Hematologic1
Not AvailableRecruitingTreatmentMalignant Lymphomas1
Not AvailableRecruitingTreatmentTransplantation, Kidney1
Not AvailableTerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Lymphoma, Mantle-Cell / Multiple Myeloma (MM) / Myelodysplasia / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentCardiac Transplantation1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Congenital Hypoplastic Anemia / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
Not AvailableTerminatedTreatmentImmunosuppressive Agents / Kidney Failure,Chronic / Transplantation, Kidney1
Not AvailableTerminatedTreatmentPolycystic Liver Disease (PLD)1
Not AvailableTerminatedTreatmentTransplantation, Kidney1
Not AvailableUnknown StatusNot AvailableCystic Fibrosis (CF) / Lung Transplant Patients1
Not AvailableUnknown StatusNot AvailableScleritis / Uveitis1
Not AvailableUnknown StatusTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Renal Cancers1
Not AvailableUnknown StatusTreatmentGlomerulosclerosis, Focal Segmental1
Not AvailableWithdrawnNot AvailablePrimary Liver Transplant1
Pharmacoeconomics
Manufacturers
  • Roche palo alto llc
  • Accord healthcare inc usa
  • Apotex corp
  • Endo pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Sandoz inc
  • Strides arcolab ltd
  • Teva pharmaceuticals usa
  • Zydus pharmaceuticals usa inc
  • Accord healthcare inc
  • Apotex inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral250 mg/1
CapsuleOral250 mg
Injection, powder, for solutionIntravenous500 mg
Injection, powder, lyophilized, for solutionIntravenous500 mg/20mL
Powder, for suspensionOral200 mg
Powder, for suspensionOral200 mg/mL
TabletOral500 mg
Tablet, film coatedOral500 mg/1
Powder, for solutionIntravenous500 mg
TabletOral500 mg/1
Tablet, coatedOral500 mg/1
Tablet, film coatedOral500 mg
Prices
Unit descriptionCostUnit
CellCept 200 mg/ml Suspension 175ml Bottle875.84USD bottle
Cellcept 500 mg vial65.03USD vial
Cellcept 500 mg tablet10.43USD tablet
Mycophenolate Mofetil 500 mg tablet8.25USD tablet
Mycophenolate 500 mg tablet7.93USD tablet
CellCept 250 mg capsule5.21USD capsule
Mycophenolate Mofetil 250 mg capsule4.13USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5688529 No1994-11-182014-11-18Us
US5543408 No1993-09-152013-09-15Us
CA2172506 No2007-07-172014-09-27Canada
CA1333285 No1994-11-292011-11-29Canada
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySlightly soluble (43 mg/mL at pH 7.4)Not Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.095 mg/mLALOGPS
logP2.17ALOGPS
logP3.47ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)9.76ChemAxon
pKa (Strongest Basic)6.19ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area94.53 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity117.1 m3·mol-1ChemAxon
Polarizability45.55 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8938
Blood Brain Barrier+0.8594
Caco-2 permeable+0.5904
P-glycoprotein substrateSubstrate0.8908
P-glycoprotein inhibitor IInhibitor0.8381
P-glycoprotein inhibitor IIInhibitor0.8061
Renal organic cation transporterInhibitor0.5379
CYP450 2C9 substrateNon-substrate0.8528
CYP450 2D6 substrateNon-substrate0.602
CYP450 3A4 substrateSubstrate0.7646
CYP450 1A2 substrateNon-inhibitor0.6878
CYP450 2C9 inhibitorNon-inhibitor0.9155
CYP450 2D6 inhibitorNon-inhibitor0.7684
CYP450 2C19 inhibitorNon-inhibitor0.9122
CYP450 3A4 inhibitorNon-inhibitor0.8316
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8664
Ames testNon AMES toxic0.6484
CarcinogenicityNon-carcinogens0.953
BiodegradationNot ready biodegradable0.658
Rat acute toxicity3.0412 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.771
hERG inhibition (predictor II)Non-inhibitor0.7653
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-0019-1741900000-022d7009668cda105e50View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-qTof , PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phthalides. These are compounds containing a 3-hydrocarbylidene-2-benzofuran-1(3H)-one moiety,.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsocoumarans
Sub ClassIsobenzofuranones
Direct ParentPhthalides
Alternative ParentsAnisoles / Alkyl aryl ethers / Fatty acid esters / Morpholines / Dicarboxylic acids and derivatives / Vinylogous acids / Trialkylamines / Amino acids and derivatives / Lactones / Carboxylic acid esters
SubstituentsPhthalide / Anisole / Alkyl aryl ether / Fatty acid ester / Dicarboxylic acid or derivatives / Morpholine / Oxazinane / Fatty acyl / Benzenoid / Vinylogous acid
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorstertiary amino compound, carboxylic ester, phenols, ether, gamma-lactone (CHEBI:8764 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna binding
Specific Function:
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in t...
Gene Name:
IMPDH1
Uniprot ID:
P20839
Uniprot Name:
Inosine-5'-monophosphate dehydrogenase 1
Molecular Weight:
55405.365 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Bremer S, Rootwelt H, Bergan S: Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells. Clin Chem. 2007 Jun;53(6):1023-9. Epub 2007 Apr 26. [PubMed:17463174 ]
  4. Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R, Fu J, Shah T, Pravica V, Hutchinson IV, Burckart GJ: IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther. 2008 May;83(5):711-7. Epub 2007 Sep 12. [PubMed:17851563 ]
  5. Sanquer S, Maison P, Tomkiewicz C, Macquin-Mavier I, Legendre C, Barouki R, Lang P: Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation. Clin Pharmacol Ther. 2008 Feb;83(2):328-35. Epub 2007 Aug 22. [PubMed:17713475 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna binding
Specific Function:
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in t...
Gene Name:
IMPDH2
Uniprot ID:
P12268
Uniprot Name:
Inosine-5'-monophosphate dehydrogenase 2
Molecular Weight:
55804.495 Da
References
  1. Vannozzi F, Filipponi F, Di Paolo A, Danesi R, Urbani L, Bocci G, Catalano G, De Simone P, Mosca F, Del Tacca M: An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc. 2004 Nov;36(9):2787-90. [PubMed:15621150 ]
  2. Bremer S, Rootwelt H, Bergan S: Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells. Clin Chem. 2007 Jun;53(6):1023-9. Epub 2007 Apr 26. [PubMed:17463174 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Uniprot Name:
UDP-glucuronosyltransferase 1-1
Molecular Weight:
59590.91 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A7
Uniprot ID:
Q9HAW7
Uniprot Name:
UDP-glucuronosyltransferase 1-7
Molecular Weight:
59818.315 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 3 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A6
Uniprot ID:
P19224
Uniprot Name:
UDP-glucuronosyltransferase 1-6
Molecular Weight:
60750.215 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Uniprot Name:
UDP-glucuronosyltransferase 1-9
Molecular Weight:
59940.495 Da
References
  1. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Uniprot Name:
UDP-glucuronosyltransferase 2B7
Molecular Weight:
60694.12 Da
References
  1. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A8
Uniprot ID:
Q9HAW9
Uniprot Name:
UDP-glucuronosyltransferase 1-8
Molecular Weight:
59741.035 Da
References
  1. Thervet E, Anglicheau D, Legendre C: [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7. [PubMed:11817210 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein kinase c binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A10
Uniprot ID:
Q9HAW8
Uniprot Name:
UDP-glucuronosyltransferase 1-10
Molecular Weight:
59809.075 Da
References
  1. Thervet E, Anglicheau D, Legendre C: [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7. [PubMed:11817210 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Triglyceride lipase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity,...
Gene Name:
CES1
Uniprot ID:
P23141
Uniprot Name:
Liver carboxylesterase 1
Molecular Weight:
62520.62 Da
References
  1. Fujiyama N, Miura M, Kato S, Sone T, Isobe M, Satoh S: Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab Dispos. 2010 Dec;38(12):2210-7. doi: 10.1124/dmd.110.034249. Epub 2010 Sep 7. [PubMed:20823294 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Methylumbelliferyl-acetate deacetylase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows high catalytic efficiency for hydrolysis of cocaine, 4-methylumbelliferyl acetate, heroin and 6-monoacetylmorphine.
Gene Name:
CES2
Uniprot ID:
O00748
Uniprot Name:
Cocaine esterase
Molecular Weight:
61806.41 Da
References
  1. Fujiyama N, Miura M, Kato S, Sone T, Isobe M, Satoh S: Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab Dispos. 2010 Dec;38(12):2210-7. doi: 10.1124/dmd.110.034249. Epub 2010 Sep 7. [PubMed:20823294 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Picard N, Cresteil T, Premaud A, Marquet P: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8. [PubMed:15570183 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Uniprot Name:
Cytochrome P450 3A5
Molecular Weight:
57108.065 Da
References
  1. Picard N, Cresteil T, Premaud A, Marquet P: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8. [PubMed:15570183 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Uniprot Name:
Cytochrome P450 2C8
Molecular Weight:
55824.275 Da
References
  1. Picard N, Cresteil T, Premaud A, Marquet P: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8. [PubMed:15570183 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Uniprot Name:
Serum albumin
Molecular Weight:
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Uniprot Name:
Solute carrier organic anion transporter family member 1B1
Molecular Weight:
76447.99 Da
References
  1. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T: Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9. Epub 2007 Sep 29. [PubMed:17906856 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Uniprot Name:
Solute carrier organic anion transporter family member 1B3
Molecular Weight:
77402.175 Da
References
  1. Michelon H, Konig J, Durrbach A, Quteineh L, Verstuyft C, Furlan V, Ferlicot S, Letierce A, Charpentier B, Fromm MF, Becquemont L: SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010 Dec;11(12):1703-13. doi: 10.2217/pgs.10.132. [PubMed:21142914 ]
  2. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T: Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9. Epub 2007 Sep 29. [PubMed:17906856 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Uniprot Name:
Canalicular multispecific organic anion transporter 1
Molecular Weight:
174205.64 Da
References
  1. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T: Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9. Epub 2007 Sep 29. [PubMed:17906856 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Uniprot Name:
ATP-binding cassette sub-family G member 2
Molecular Weight:
72313.47 Da
References
  1. Miura M, Kagaya H, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T: Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64. doi: 10.1097/FTD.0b013e3181838063. [PubMed:18695635 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Uniprot Name:
Multidrug resistance protein 1
Molecular Weight:
141477.255 Da
References
  1. Miura M, Kagaya H, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T: Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64. doi: 10.1097/FTD.0b013e3181838063. [PubMed:18695635 ]
Drug created on June 13, 2005 07:24 / Updated on August 02, 2017 16:26